Syngene International Ltd - 539268 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached the details of meetings to be held with Analysts/Institutional investors. Syngene International Ltd - 539268 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached the details of meetings to be held with Analysts/Institutional investors. Syngene International Ltd - 539268 - Announcement under Regulation 30 (LODR)-Newspaper Publication
In continuation to our letter dated January 23, 2023, regarding outcome of the Board Meeting and financials for the quarter ended December 31, 2022, please find enclosed herewith the copy of newspaper publication of the financials in Financial Express (All India Edition) and Vijayavani (Bengaluru Edition) published on January 25, 2023. Syngene International Ltd - 539268 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached the details of meetings to be held with Analysts/Institutional investors.
Syngene: Timeline for follow-through in Zoetis contract key catalyst to watch
Another growth lever to watch in manufacturing is that of the Mangalore API facility. Here the USFDA approval is expected in H2FY24.
Growth, expansion aid Syngene in Q3
The revenues from operations at ?786 cr grew 23% y-o-y during Q3 taking the 9 months growth to 19% y-o-y Syngene International Ltd - 539268 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Intimation of audio recording for Q3 FY23 post earnings call. Q3FY23 Quarterly Result Announced for Syngene International Ltd.
Pharmaceuticals firm Syngene International announced Q3FY23 results: Q3FY23: Total Revenue Rs 8,031 million Reported EBITDA Rs 2,482 million Profit After Tax Rs 1,097 million EBITDA Margin at 30.9% and PAT Margin at 13.7% Commenting on the results, Jonathan Hunt, Managing Director and Chief Executive Officer, Syngene International Limited, said, "We continue to see good demand in the main client markets of US and Europe which - combined with strong execution and forward planning - has helped us deliver solid revenue growth in the third quarter. We are pleased to report positive performances from all divisions this quarter. Growth in our research divisions, Discovery Services and the Dedicated Centres, was solid. In Development Services, repeat orders from existing clients, as well as an increase in the number of collaborations with emerging biopharma companies drove a robust performance. In Manufacturing, the highlight of the quarter was the successful inspection of our biologics facilities by the US FDA, EMA and MHRA. With Good Manufacturing Practice (cGMP) certifications from the regulatory agencies in place, the Company is well positioned to fulfil its long-term contract with Zoetis and progress its biologics growth strategy. Based on our strong performance to date, we are confident of meeting the upgraded annual revenue growth guidance of high teens.” Sibaji Biswas, Chief Financial Officer, Syngene International Limited added, “Overall financial performance for the nine months ending 31st December 2022 was in line with our upgraded guidance and, with strong underlying revenue growth and stable margin delivery, we are on track to achieve our guidance for the year. In line with the global trend, we are also facing inflationary pressures, but we have been largely successful in navigating such issues to date and we remain confident about the positive future potential for our business.” Result PDF Syngene International Ltd - 539268 - Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)
This is with reference to our letter no : Syn/CS/SE/PR/2022-23/Jan/07 dated January 23,2023 intimating the press release titled 'Syngene reports strong third quarter results: Revenue up to Rs. 803 crores, PAT up to Rs.110 crores'. It may kindly be noted that the date on the press release was inadvertently mentioned as January 23, 2022, instead of January 23, 2023. The revised press release with the correct date is enclosed herewith. Syngene International Ltd - 539268 - Announcement under Regulation 30 (LODR)-Investor Presentation
With reference to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the Investor Presentation for the quarter ended December 31, 2022. The Company will use this presentation for any meeting scheduled with analysts or institutional investors up to March 31, 2023.